These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36576693)

  • 1. Deterioration of visual quality and acuity as the first sign of ceroid lipofuscinosis type 3 (CLN3), a rare neurometabolic disease.
    Purzycka-Olewiecka JK; Hetmańczyk-Sawicka K; Kmieć T; Szczęśniak D; Trubicka J; Krawczyński M; Pronicki M; Ługowska A
    Metab Brain Dis; 2023 Feb; 38(2):709-715. PubMed ID: 36576693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
    de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
    J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
    Drack AV; Miller JN; Pearce DA
    J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium.
    Zhong Y; Mohan K; Liu J; Al-Attar A; Lin P; Flight RM; Sun Q; Warmoes MO; Deshpande RR; Liu H; Jung KS; Mitov MI; Lin N; Butterfield DA; Lu S; Liu J; Moseley HNB; Fan TWM; Kleinman ME; Wang QJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165883. PubMed ID: 32592935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome.
    Appu AP; Bagh MB; Sadhukhan T; Mondal A; Casey S; Mukherjee AB
    J Inherit Metab Dis; 2019 Sep; 42(5):944-954. PubMed ID: 31025705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).
    Chen FK; Zhang X; Eintracht J; Zhang D; Arunachalam S; Thompson JA; Chelva E; Mallon D; Chen SC; McLaren T; Lamey T; De Roach J; McLenachan S
    Doc Ophthalmol; 2019 Feb; 138(1):55-70. PubMed ID: 30446867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).
    Sarpong A; Schottmann G; Rüther K; Stoltenburg G; Kohlschütter A; Hübner C; Schuelke M
    Clin Genet; 2009 Jul; 76(1):38-45. PubMed ID: 19489875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel in-frame mutation in
    Sher M; Farooq M; Abdullah U; Ali Z; Faryal S; Zakaria M; Ullah F; Bukhari H; Møller RS; Tommerup N; Baig SM
    Int J Neurosci; 2019 Sep; 129(9):890-895. PubMed ID: 30892110
    [No Abstract]   [Full Text] [Related]  

  • 9. Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
    Bosch ME; Aldrich A; Fallet R; Odvody J; Burkovetskaya M; Schuberth K; Fitzgerald JA; Foust KD; Kielian T
    J Neurosci; 2016 Sep; 36(37):9669-82. PubMed ID: 27629717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile neuronal ceroid lipofuscinosis (Batten disease) CLN3 mutation (Chrom 16p11.2) with different phenotypes in a sibling pair and low intensity in vivo autofluorescence.
    Mantel I; Brantley MA; Bellmann C; Robson AG; Holder GE; Taylor A; Anderson G; Moore AT
    Klin Monbl Augenheilkd; 2004 May; 221(5):427-30. PubMed ID: 15162299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synapse alterations precede neuronal damage and storage pathology in a human cerebral organoid model of CLN3-juvenile neuronal ceroid lipofuscinosis.
    Gomez-Giro G; Arias-Fuenzalida J; Jarazo J; Zeuschner D; Ali M; Possemis N; Bolognin S; Halder R; Jäger C; Kuper WFE; van Hasselt PM; Zaehres H; Del Sol A; van der Putten H; Schöler HR; Schwamborn JC
    Acta Neuropathol Commun; 2019 Dec; 7(1):222. PubMed ID: 31888773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.
    Chan CH; Mitchison HM; Pearce DA
    Hum Mol Genet; 2008 Nov; 17(21):3332-9. PubMed ID: 18678598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis.
    Hersrud SL; Kovács AD; Pearce DA
    Biochim Biophys Acta; 2016 Jul; 1862(7):1324-36. PubMed ID: 27101989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular morphology and function in juvenile neuronal ceroid lipofuscinosis (CLN3) in the first decade of life.
    Preising MN; Abura M; Jäger M; Wassill KH; Lorenz B
    Ophthalmic Genet; 2017; 38(3):252-259. PubMed ID: 27486012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The parent and family impact of CLN3 disease: an observational survey-based study.
    Schulz A; Patel N; Brudvig JJ; Stehr F; Weimer JM; Augustine EF
    Orphanet J Rare Dis; 2024 Mar; 19(1):125. PubMed ID: 38500130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.
    Wibbeler E; Nickel M; Schwering C; Schulz A; Mink JW
    Eur J Paediatr Neurol; 2022 May; 38():62-65. PubMed ID: 35427884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From gene to disease; from CLN1, CLN2 and CLN3 to neuronal ceroid lipofuscinosis].
    Taschner PE; Losekoot M; Breuning MH; Hofman I; van Diggelen OP
    Ned Tijdschr Geneeskd; 2005 Feb; 149(6):300-3. PubMed ID: 15730038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coding sequence and exon/intron organization of the canine CLN3 (Batten disease) gene and its exclusion as the locus for ceroid-lipofuscinosis in English setter dogs.
    Shibuya H; Liu PC; Katz ML; Siakotos AN; Nonneman DJ; Johnson GS
    J Neurosci Res; 1998 May; 52(3):268-75. PubMed ID: 9590435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
    Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
    Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First case of genetically confirmed CLN3 disease in Chinese with cDNA sequencing revealing pathogenicity of a novel splice site variant.
    Lau NKC; Ching CK; Lee HHC; Chak WKM; Kwan Shing N; Hanchard NA; Mak CM
    Clin Chim Acta; 2018 Nov; 486():151-155. PubMed ID: 30053402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.